Gain Therapeutics Inc is a biotechnology business based in the US. Gain Therapeutics Inc shares (GANX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.03 – an increase of 7.98% over the previous week. Gain Therapeutics Inc employs 23 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.03 |
|---|---|
| 52-week range | $0.89 - $3.19 |
| 50-day moving average | $1.96 |
| 200-day moving average | $1.85 |
| Wall St. target price | $8.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.89 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.03 from 2025-05-05
| 1 week (2025-04-29) | 7.98% |
|---|---|
| 1 month (2025-04-07) | 23.03% |
| 3 months (2025-02-07) | -22.22% |
| 6 months (2024-11-07) | -8.97% |
| 1 year (2024-05-07) | -30.00% |
|---|---|
| 2 years (2023-05-05) | -63.09% |
| 3 years (2022-05-06) | 3.43 |
| 5 years (2020-05-03) | N/A |
| Gross profit TTM | $-10,650,481 |
|---|---|
| Return on assets TTM | -82.8% |
| Return on equity TTM | -204.95% |
| Profit margin | 0% |
| Book value | $0.27 |
| Market Capitalization | $57.2 million |
TTM: trailing 12 months
We're not expecting Gain Therapeutics Inc to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Gain Therapeutics Inc's shares have ranged in value from as little as $0.89 up to $3.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gain Therapeutics Inc's is 0.188. This would suggest that Gain Therapeutics Inc's shares are less volatile than average (for this exchange).
To put Gain Therapeutics Inc's beta into context you can compare it against those of similar companies.
Gain Therapeutics, Inc. , a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of Parkinson's disease, currently in a Phase 1b study in people with Parkinson's disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. The company was founded in 2017 and is based in Bethesda, Maryland. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .